Published in Gene Therapy Weekly, April 13th, 2006
"Replication competent oncolytic HSV with broad-spectrum activity against various cancers, including prostate cancer, exert a dual effect by their direct cytocidal action and by eliciting tumor-specific immunity. These viruses can deliver immunoregulatory molecules to tumors so as to enhance the cumulative antitumor response," wrote S. Varghese and colleagues, Harvard University.
They continued, "This is particularly desirable for prostate cancers, which are usually poorly immunogenic. Initial studies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.